Teladoc Health (NYSE:TDOC) Hits New 12-Month Low Following Weak Earnings

Teladoc Health, Inc. (NYSE:TDOC)’s stock price hit a new 52-week low during mid-day trading on Friday following a dissappointing earnings announcement. The company traded as low as $12.65 and last traded at $13.36, with a volume of 2157832 shares traded. The stock had previously closed at $13.33.

The health services provider reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.02). Teladoc Health had a negative return on equity of 9.22% and a negative net margin of 8.47%. The company had revenue of $646.13 million during the quarter, compared to analysts’ expectations of $637.31 million. During the same period in the previous year, the company earned ($0.37) EPS. Teladoc Health’s quarterly revenue was up 2.7% on a year-over-year basis.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TDOC. Citigroup cut their target price on Teladoc Health from $21.00 to $19.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 21st. Canaccord Genuity Group decreased their target price on Teladoc Health from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Friday. Royal Bank of Canada dropped their price objective on shares of Teladoc Health from $25.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday. Barclays cut their target price on Teladoc Health from $25.00 to $20.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, SVB Leerink assumed coverage on shares of Teladoc Health in a research report on Monday, February 26th. They issued a “market perform” rating and a $17.00 target price for the company. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $19.67.

Insider Buying and Selling

In other news, COO Michael Willem Waters sold 4,523 shares of the business’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $19.18, for a total transaction of $86,751.14. Following the sale, the chief operating officer now directly owns 38,570 shares of the company’s stock, valued at $739,772.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Teladoc Health news, insider Laizer Kornwasser sold 7,882 shares of Teladoc Health stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $19.18, for a total transaction of $151,176.76. Following the transaction, the insider now directly owns 57,223 shares in the company, valued at approximately $1,097,537.14. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Michael Willem Waters sold 4,523 shares of the stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $19.18, for a total value of $86,751.14. Following the completion of the sale, the chief operating officer now owns 38,570 shares of the company’s stock, valued at approximately $739,772.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 135,441 shares of company stock worth $2,038,251. Corporate insiders own 1.63% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TDOC. ARK Investment Management LLC raised its holdings in shares of Teladoc Health by 4.5% during the 4th quarter. ARK Investment Management LLC now owns 21,224,565 shares of the health services provider’s stock valued at $457,389,000 after purchasing an additional 912,692 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Teladoc Health by 11.8% in the 4th quarter. Vanguard Group Inc. now owns 17,515,127 shares of the health services provider’s stock worth $377,451,000 after acquiring an additional 1,855,480 shares during the period. Dimensional Fund Advisors LP boosted its stake in Teladoc Health by 25.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,834,422 shares of the health services provider’s stock worth $82,636,000 after buying an additional 767,999 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Teladoc Health by 6.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,654,116 shares of the health services provider’s stock valued at $35,646,000 after buying an additional 104,531 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Teladoc Health by 9.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 658,435 shares of the health services provider’s stock worth $12,240,000 after purchasing an additional 57,989 shares during the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.

Teladoc Health Trading Down 2.4 %

The company’s fifty day moving average price is $15.01 and its two-hundred day moving average price is $17.77. The company has a market cap of $2.20 billion, a price-to-earnings ratio of -9.71 and a beta of 0.94. The company has a quick ratio of 3.47, a current ratio of 3.54 and a debt-to-equity ratio of 0.66.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.